This is the first report of the relationship between TXNIP SNPs and the response to the first course of cytarabine- and anthracycline- containing induction and the long-term relapse rate of AML patients, which has important implications for using these regimens in AML treatment. This evidence concerns the gene TXNIP and acute myeloid leukemia.